Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET.
Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders, has announced a fireside chat scheduled for February 18, 2025, at 12:00 pm ET. CEO Kirk Huntsman will engage with Water Tower Research's senior analyst Do Kim to discuss several key topics.
The discussion will cover the company's Vivos CARE devices for treating obstructive sleep apnea (OSA) and snoring in adults, as well as moderate to severe OSA in children aged 6-17. Key points to be addressed include the company's strategic shift to a medical-based business model, efforts to establish partnerships with physician-based sleep groups, OSA market dynamics, and the positioning of Vivos CARE devices in OSA treatment.
The event will be listen-only, with a replay available for 30 days in the Investor Relations section of the Vivos website.
Vivos Therapeutics (NASDAQ: VVOS), un'azienda di dispositivi medici e tecnologia focalizzata sui disturbi respiratori correlati al sonno, ha annunciato un incontro informale programmato per il 18 febbraio 2025, alle 12:00 ET. Il CEO Kirk Huntsman dialogherà con l'analista senior di Water Tower Research, Do Kim, per discutere diversi temi chiave.
La discussione tratterà dei dispositivi Vivos CARE per il trattamento dell'apnea ostruttiva del sonno (OSA) e del russare negli adulti, così come dell'OSA da moderata a grave nei bambini di età compresa tra 6 e 17 anni. I punti principali da affrontare includeranno il cambiamento strategico dell'azienda verso un modello di business basato sulla medicina, gli sforzi per stabilire partnership con gruppi di medici specializzati nel sonno, la dinamica del mercato OSA e il posizionamento dei dispositivi Vivos CARE nel trattamento dell'OSA.
L'evento sarà solo in ascolto, con una registrazione disponibile per 30 giorni nella sezione Relazioni con gli Investitori del sito web di Vivos.
Vivos Therapeutics (NASDAQ: VVOS), una empresa de dispositivos médicos y tecnología enfocada en trastornos respiratorios relacionados con el sueño, ha anunciado un chat informal programado para el 18 de febrero de 2025, a las 12:00 p.m. ET. El CEO Kirk Huntsman dialogará con el analista senior de Water Tower Research, Do Kim, para discutir varios temas clave.
La discusión abordará los dispositivos Vivos CARE para tratar la apnea obstructiva del sueño (OSA) y el ronquido en adultos, así como la OSA moderada a grave en niños de 6 a 17 años. Los puntos clave a tratar incluyen el cambio estratégico de la empresa hacia un modelo de negocio médico, los esfuerzos para establecer asociaciones con grupos de médicos especializados en sueño, la dinámica del mercado de OSA y el posicionamiento de los dispositivos Vivos CARE en el tratamiento de la OSA.
El evento será solo para escuchar, con una repetición disponible durante 30 días en la sección de Relaciones con Inversores del sitio web de Vivos.
비보스 테라퓨틱스 (NASDAQ: VVOS), 수면 관련 호흡 장애에 중점을 둔 의료 기기 및 기술 회사가 2025년 2월 18일 오후 12시(ET)에 예정된 화상 대화를 발표했습니다. CEO 커크 헌츠먼은 워터 타워 리서치의 수석 분석가 도 킴과 여러 주요 주제에 대해 논의할 예정입니다.
논의는 성인의 폐쇄성 수면 무호흡증 (OSA)과 코골이, 6세에서 17세 사이의 어린이의 중등도에서 중증 OSA 치료를 위한 비보스 CARE 장치를 다룰 것입니다. 다룰 주요 사항으로는 의료 기반 비즈니스 모델로의 전략적 전환, 의사 기반 수면 그룹과의 파트너십 구축 노력, OSA 시장 역학 및 OSA 치료에서 비보스 CARE 장치의 위치가 포함됩니다.
이벤트는 청취 전용으로 진행되며, 비보스 웹사이트의 투자자 관계 섹션에서 30일 동안 재생할 수 있습니다.
Vivos Therapeutics (NASDAQ: VVOS), une entreprise de dispositifs médicaux et de technologie axée sur les troubles respiratoires liés au sommeil, a annoncé un échange informel prévu pour le 18 février 2025 à 12h00 ET. Le PDG Kirk Huntsman s'entretiendra avec l'analyste senior de Water Tower Research, Do Kim, pour discuter de plusieurs sujets clés.
La discussion portera sur les dispositifs Vivos CARE pour le traitement de l'apnée obstructive du sommeil (OSA) et du ronflement chez les adultes, ainsi que de l'OSA modérée à sévère chez les enfants âgés de 6 à 17 ans. Les points clés à aborder incluront le changement stratégique de l'entreprise vers un modèle commercial basé sur la médecine, les efforts visant à établir des partenariats avec des groupes de médecins spécialisés dans le sommeil, la dynamique du marché de l'OSA et le positionnement des dispositifs Vivos CARE dans le traitement de l'OSA.
L'événement sera uniquement en écoute, avec un replay disponible pendant 30 jours dans la section Relations Investisseurs du site web de Vivos.
Vivos Therapeutics (NASDAQ: VVOS), ein Unternehmen für medizinische Geräte und Technologien, das sich auf schlafbezogene Atemstörungen spezialisiert hat, hat ein informelles Gespräch für den 18. Februar 2025 um 12:00 Uhr ET angekündigt. CEO Kirk Huntsman wird mit dem leitenden Analysten von Water Tower Research, Do Kim, mehrere zentrale Themen besprechen.
In der Diskussion werden die Vivos CARE Geräte zur Behandlung von obstruktiver Schlafapnoe (OSA) und Schnarchen bei Erwachsenen sowie von moderater bis schwerer OSA bei Kindern im Alter von 6 bis 17 Jahren behandelt. Wichtige Punkte, die angesprochen werden, umfassen den strategischen Wandel des Unternehmens zu einem medizinisch orientierten Geschäftsmodell, die Bemühungen um Partnerschaften mit schlafmedizinischen Gruppen und die Marktbedingungen für OSA sowie die Positionierung der Vivos CARE Geräte in der OSA-Behandlung.
Die Veranstaltung wird nur zum Zuhören sein, mit einer Wiederholung, die 30 Tage lang im Bereich Investor Relations auf der Website von Vivos verfügbar sein wird.
- None.
- None.
LITTLETON, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced that the Company’s CEO Kirk Huntsman will participate in a fireside chat with Do Kim, senior research analyst of Water Tower Research ("WTR") on Tuesday, February 18, 2025, at 12:00 pm ET.
Mr. Huntsman will provide an overview of the Company and its Vivos CARE devices for OSA, the strategic shift to a medical-based business model, its efforts to secure alliances and partnerships with physician-based sleep groups, OSA market dynamics, and how Vivos CARE devices fit in the OSA treatment paradigm.
To register for this listen-only event, please visit:
Fireside Chat Registration Link
The replay of the fireside chat will be available for 30 days in the "Investor Relations" section on the Company’s website at https://vivos.com.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults and children. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical, and cost-effective solution for treating mild to severe OSA in adults and moderate to severe OSA in children. It has proven effective in over 47,000 patients treated worldwide by more than 2,000 trained dentists.
The Vivos Method includes treatment regimens that employ proprietary CARE appliance therapy and other modalities that alter the size, shape, and position of the jaw and soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA in adults and moderate-to-severe OSA in children ages 6 to 17, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method. Vivos also employs a marketing and distribution model where it collaborates with sleep-treatment providers to offer patients OSA treatment options and help promote sales of its appliances.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, the fireside chat referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual future impact of the initiatives and corporate achievements described herein on Vivos’ future revenues and results of operations and the anticipated benefits of the Company’s new marketing and distribution model described herein) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all or maintain its Nasdaq listing (v) market and other conditions, and (vi) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Vivos Investor Relations and Media Contact:
Bradford Amman, CFO
investors@vivoslife.com
FAQ
When is the Vivos Therapeutics (VVOS) fireside chat with Water Tower Research?
What topics will be covered in the VVOS fireside chat?
How long will the VVOS fireside chat replay be available?
What age groups does VVOS's OSA treatment target?
Where can investors access the VVOS fireside chat replay?
